Third-Largest Biotech ETF Up 20% Year-to-Date

After slumping last year, the SPDR S&P Biotech ETF (NYSEArca: XBI), the third-largest biotechnology exchange traded fund, is up 20% year-to-date, putting the equal-weight biotechnology fund in a new bull market. Some market observers see more upside coming for the popular biotechnology ETF. There are other catalysts to consider, including that the U.S. economy moving…Click to read more at ETFtrends.com.